Phase 2 N=143 Evaluate Safety, Efficacy and Pharmacokinetics
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=91 Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
Healthy
Primary: Number of Participants With Drug-related Adverse Events (AEs) — 3; 1; 4; 1 Participants
Phase 1 N=72 Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
Hypertension and Chronic Heart Failure
Primary: Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period — 28; 0; 0; 0 % of subject…
Phase 1 N=9 The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions — 112,236.7; 154,676.6 ng*hr/mL
Phase 1 N=66 A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
Plaque Psoriasis
Primary: Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1 — 114.2; 110.6; 108.7; 102.8 millimeter of mercury (mmHg)
Phase 1 N=60 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs
Phase 1 N=37 Four Arm Food Effect Study of Fenofibric Acid Tablets
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 9,806.74; 9,854.39; 7,950.75; 12,061.67 ng/mL
Phase 1 N=88 Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 0; 16.7; 33.3; 16.7 percentage of participants
Phase 1 N=88 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
Autistic Disorder · Autism Spectrum Disorder · Child Development Disorders, Pervasive
Primary: Parts 1, 2 and 3: Percentage of Participants With Adverse Events — 2; 2; 2; 4 Participants
Phase 1 N=14 A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
Pharmacokinetic
Primary: Cmax — 508.6; 384.5; 289.5; 499.5 nmol/L
Phase 1 N=16 Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone — 2165; 2209; 2073; 1955 ng·h/mL
Phase 1 N=66 SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
Eosinophilic Esophagitis (EoE)
Primary: Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant — 1; 0; 1; 2 Participants
Phase 1 N=83 Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
Healthy
Primary: Number of Participants With Drug-related Adverse Events (AE) — 3; 1; 2; 1 Participants
Phase 1 N=48 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests — 0.0; 0.0; 0.0; 0.0 percentage of…
Phase 1 N=30 Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
Advanced Solid Malignancy, · Safety and Tolerability, · Pharmacokinetics, Pharmacodynamics,
Primary: Ratio of Css,Max for Day 4 to Day 11 — 1.02; 0.67 Ratio
Phase 1 N=28 A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs). — 1; 1; 1; 2 Participants
Phase 1 N=19 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791
Healthy Volunteers · Insulin Resistance
Primary: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug — 0; 0; 0; 0 participants
Phase 1 N=30 Food-Effect Study in Healthy Participants
Healthy
Primary: Pharmacokinetics - Cmax (ng/mL) — 394.7; 322.8 ng/mL
Phase 1 N=6 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
Healthy
Primary: Number of Treatment Related Adverse Events — 3; 4; 0; 3 Number of events
Phase 1 N=15 A Relative Bioavailability and Food Effect Study of New Formulations
Chronic Inflammatory Disorder · Arthritis, Rheumatoid
Primary: Pharmacokinetics: Plasma Concentration-Time Curve (AUC) — 1670; 1710; 1510; 1700 nanomoles*hours per liter (nmol*h/L)
N/A N=30 Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers
Diabetes Mellitus, Type 2
Primary: Maximum Observed Concentration (Cmax) — 884.297; 963.384; 942.653 Nanograms per milliliter (ng/mL) — p=0.1413
Phase 1 N=45 Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Primary: Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a…
Phase 1 N=81 Safety of Single Rising Doses and Relative Bioavailability of BI 691751
Healthy
Primary: AUC0-72h (Part II) — 2740; 3050; 2800 nmol*h/L
Phase 1 N=48 Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers
Healthy
Primary: Number of Subjects Experiencing TEAEs. — 3; 0; 4; 1 participants
Phase 1 N=80 To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706
Healthy
Primary: Number of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 16.7 Percentage of participants
Phase 1 N=99 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects
Healthy
Primary: Part A: Number of Participants With Adverse Events — 4; 3; 4; 3 participants
Phase 1 N=64 A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
Autoimmune Diseases
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 0; 0; 0 participants
Phase 1 N=58 A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules
Hyperammonemia
Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 0; 1; 2; 1 Participants
Phase 1 N=76 A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 6.3; 0.0; 16.7; 0.0 Percentage of participants
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 16.7; 44.4; 11.1 Percentage of participants